Text Size
S
M
L
Listen
Santen Global
menu
Patients
Healthcare Professionals
Careers
Investors
Listen
Tap on the left to use.
Who We Are
Message
Message from the CEO
Corporate Story
Corporate Story
CORE PRINCIPLE / Our Commitment
CORE PRINCIPLE / Our Commitment
Our Values
Our Values
History
History of Santen
Corporate Executives
Corporate Executives
Corporate Governance
Corporate Governance
Policies
Policies and Statements
Company Infomation
Overview / Map
Global Operation
What We Do
MTP & Santen 2030
Medium-term Management Plan
Santen 2030
Efforts to Enhance Patients' Satisfaction
Efforts to Enhance Product Safety
Efforts to Enhance Product Usability
Efforts to Address Untreated Patients
Research & Development
Research & Development
The Ophthalmic Product Process: R&D
Clinical Trial Information
Partnering
Santen's Partnership
Our Partners
Partnering Contact
Production
Production
Safety and Quality Assurance
The Ophthalmic Production Process: Production
Sales & Marketing
Sales & Marketing
Our Stories
Sustainability
Sustainability
Our Sustainability Commitment
Sustainability at Santen
Social
Access to Healthcare
Research & Development in Ophthalmology
Product Quality & Safety
Supply Chain
Human Rights
Talent
Digital Transformation (DX)
Governance
Corporate Governance
Compliance
Ethical Marketing
Risk Management
Information Security
Environment
Environmental initiatives
Measures against Climate Change
Environmental Load Reduction
Biodiversity
Disclosures Based on the TCFD Recommendations
Inclusion
Inclusive Society Santen Promotes
Inclusion Starting from Blind Football
Together with Society
With Employees
Related Information
Participating in the UN Global Compact
Social Contribution Activities
Stakeholder Engagement
Environment Data (up-to-date)
Social Data (up-to-date)
Governance Data (up-to-date)
GRI Standards Content Index
Sustainability Library
External Assessment
News
News
Show All
Press Release
IR News
Information
HOME
News
2019
IR News
2019 IR News
RSS
IR News
12.23.2019
Santen Announces Topline Result from Phase II Clinical Trial of DE-127 for Patients with Mild and Moderate Myopia
12.20.2019
Bayer Yakuhin and Santen Pharmaceutical extend co-promotion agreement for Eylea (aflibercept intravitreal injection) in Japan
11.27.2019
Launch of Alesion LX Ophthalmic Solution 0.1% in Japan
11.06.2019
Santen Reports the 2nd Quarter Fiscal 2019 Consolidated Performance
11.06.2019
Santen Announces Proposed Dividend Change
10.18.2019
Santen Donates to the Disaster Caused by Typhoon Hagibis
09.20.2019
Receipt of NDA Approval of Alesion LX for anti-allergy in Japan, and Joint Sales Promotion Contract with Mitsubishi Tanabe Pharma
09.06.2019
Sponsorship Agreement for IBSA Blind Football Asian Championships 2019 signed between Santen, IBF Foundation, and JBFA
08.30.2019
Santen Announces Topline Pivotal Data for DE-128 (MicroShunt) Demonstrating Reductions in Intraocular Pressure and Medication Use in Patients
08.01.2019
Santen Reports the 1st Quarter Fiscal 2019 Consolidated Performance
07.24.2019
Notice on the Completion of Disposal of Treasury Shares Under Restricted Stock-Linked Remuneration Program
07.22.2019
Corporate Governance Report
07.03.2019
Santen Included in All Four ESG Investment Indices Selected by GPIF
06.26.2019
R&D collaboration and Option & Licence Agreement with Oxford Biomedica for development of gene therapy vectors for inherited retinal disease
06.25.2019
Notice on the Disposal of Treasury Shares Under Restricted Stock-Linked Remuneration Program
06.11.2019
Santen Chooses SAP S/4HANA Cloud and Other SAP Solutions to Reform Key Operation System and Strengthen Global Management Structure
05.09.2019
Notice of Board of Director and Corporate Auditor Nominations
05.09.2019
Santen Reports Fiscal 2018 Consolidated Performance
04.26.2019
Santen and Glaukos Enter into Collaboration and Distribution Agreement for Exclusive Distribution of the MicroShunt (DE-128) in the United States
04.18.2019
Santen Announces Launch of LENTIS Comfort, Low-Add Segmental Intraocular Lens for Cataract Treatment in Japan
03.27.2019
Santen Announces Cancellation of Treasury Shares
03.25.2019
Santen Announces Completion of Repurchase of Own Shares
03.13.2019
Notice of Corporate Officer Appointments
03.08.2019
Santen to Conduct Activities to Raise Disease Awareness during World Glaucoma Week, March 10 to 16
03.06.2019
Santen Selected and Launches Gene Therapy Drug Research and Development Project for Inherited Ocular Disease Treatment for CiCLE Program
03.06.2019
Santen Selected and Launches Photo-Crosslinking Research and Development Project for Pathologic Myopia Treatment for CiCLE Program
03.01.2019
Santen Announces Status of Repurchase of Own Shares
02.20.2019
Santen Announces Repurchase of Own Shares
02.05.2019
Santen Reports the 3rd Quarter Fiscal 2018 Consolidated Performance
01.31.2019
Santen Hosts Event to Raise Public Awareness of Importance of Continued Glaucoma Treatment Prior to Sponsoring World Glaucoma Week in March
01.25.2019
Santen's Tampere manufacturing facility to be acquired by NextPharma
01.08.2019
Santen Updates Pipeline in Corporate Presentation of January 8, 2019
News Archive